Norethindrone Acetate And Ethinyl Estradiol Tablet
Product Images NDC 68462-132

10 FDA label images from Glenmark Pharmaceuticals Inc., Usa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Norethindrone Acetate And Ethinyl Estradiol (NDC 68462-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure1 (Image 03)

Structure1 (Image 03)
Chemical structure of Ethinyl Estradiol, identified in the image by its molecular diagram including labeled functional groups.*
FDA Label Image

Structure2 (Image 04)

Structure2 (Image 04)
Chemical structure of Norethindrone Acetate shown as a molecular diagram with labeled atoms and bonds, depicting its steroidal framework.*
FDA Label Image

Table (Table 2)

Table (Table 2)
A bar chart titled 'Circulatory Disease Mortality Rates per 100,000 Women Years by Age, Smoking Status and Oral Contraceptive Use' displaying mortality rates for four age groups (15-24, 25-34, 35-44, 45+). The data are segmented by smoking status and contraceptive use: ever-users (non-smokers and smokers) and controls (non-smokers and smokers). Mortality rates increase notably with age, especially among smoker ever-users, highlighted by the tallest bars in the 45+ age group.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A forest plot chart showing effect estimates from several studies comparing combined oral contraceptive (COC) use versus never use. The left side lists study names and years, with points and horizontal lines representing odds ratios (OR), relative risks (RR), or hazard ratios (HR) and their confidence intervals plotted against an effect estimate axis ranging approximately from -1.5 to 2.0, with 1.0 as the reference line.*
FDA Label Image
FDA Label Image

Blister1 (Blister1)

Blister1 (Blister1)
An oral medication calendar diagram for Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/0.02 mg, showing a 3-week schedule with labeled circles for each day of the week (Sunday through Saturday) indicating where to mark or place each daily tablet dose. Arrows guide the sequence for taking the tablets weekly from start through week 3.*
FDA Label Image

Blister2 (Blister2)

Blister2 (Blister2)
An illustrated weekly dose tracker for Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/0.02 mg. It shows a 21-day horizontal layout with circles for each day of the week over three weeks, labeled SUN to SAT with arrows indicating the sequence of daily tablet intake.*
FDA Label Image

Logo1 (Logo1)

FDA Label Image

Pouch (Pouch)

Pouch (Pouch)
Label for Norethindrone Acetate and Ethinyl Estradiol Tablets, USP 1 mg/0.02 mg, oral tablet by Glenmark Pharmaceuticals Inc., USA. The label indicates a 21-day regimen with one blister containing 21 white to off-white tablets. Storage instructions and manufacturer details from Glenmark Pharmaceuticals Limited, India, are included, along with a barcode and contact information.*
FDA Label Image

Carton (Carton)

Carton (Carton)
Packaging label for Norethindrone Acetate and Ethinyl Estradiol Tablets, USP, 1 mg/0.02 mg oral tablets. The label indicates a 21-day regimen with 3 blisters each containing 21 tablets. The product is distributed by Glenmark Pharmaceuticals Inc., USA, and includes barcodes along with dosage and storage instructions on the carton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.